Cogent Biosciences, Inc. (COGT)
Health Care ยท Pharmaceutical Preparations
Cogent Biosciences, Inc. (COGT) is listed on Nasdaq, where its shares have traded since March 29, 2018. SentiSense covers Cogent Biosciences, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Andrew Robbins is its chief executive officer. The company reports 258 employees, and its corporate website is www.cogentbio.com.
About Cogent Biosciences, Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Latest reported results
Cogent Biosciences reported revenue of $0.00 for Q3 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 313 institutions reported holding COGT, with 193.1 million shares worth $7.5 billion in aggregate. The largest reported holders were FMR, BlackRock and Vanguard. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on COGT
- COGT sentiment: whether news and social coverage of Cogent Biosciences, Inc. leans bullish or bearish, and the stories driving it.
- COGT ownership: all 313 reporting institutions, plus insider and congressional trades.
- COGT financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Cogent Biosciences, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Cogent Biosciences, Inc. do?
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases.
What sector is COGT in?
SentiSense classifies Cogent Biosciences, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does COGT stock trade?
Cogent Biosciences, Inc. (COGT) is listed on Nasdaq, where its shares have traded since March 29, 2018.
Who is the CEO of Cogent Biosciences, Inc.?
Andrew Robbins is the chief executive officer of Cogent Biosciences, Inc..